KLA-Tencor Corporation (NASDAQ:KLAC) possesses the largest downside in the risk due to higher relative valuation and notes many stocks are pricing in order weakness, according to Goldman. The firm gives shares a Neutral rating.
Don’t Miss: Wall Street Brief: Sirius XM Subscriber UPDATE, Alcoa to Kick-Off Earnings Season.
Celgene Corporation (NASDAQ:CELG): Following Reuters’ report that Celgene had become a possible second bidder for the acquisition of Human Genome Sciences (NASDAQ:HGSI), Rodman & Renshaw vocalized that the move would be somewhat irrational for Celgene. The firm states that shareholders of Celgene would not have much tolerance for the sizable and possibly dilutive acquisition. Rodman & Renshaw maintains an Outperform rating with a $76 price target on the shares.
To read the full, original article click on this link: Celgene and Human Genome Might Marry and 4 Analyst Insights | Wall St. Cheat Sheet
